Opportunity
Federal Register #811-22684
SEC Notice: Daxor Corporation Application for Deregistration as Investment Company
Buyer
Securities and Exchange Commission
Posted
September 09, 2026
Identifier
811-22684
This notice from the Securities and Exchange Commission (SEC) concerns Daxor Corporation's application for deregistration as an investment company. - Government Buyer: - Securities and Exchange Commission (SEC) - OEM/Vendor Mentioned: - Daxor Corporation - Products/Services Referenced: - Volumex Test Kits (used with BVA Companion Analyzer) - BVA Companion Analyzer (medical device) - Key Details: - Daxor Corporation is now primarily a radiopharmaceutical and medical device manufacturer - The company no longer holds investment securities and has ceased to be an investment company - No products, part numbers, or purchase quantities are requested - The notice is informational and does not solicit bids, proposals, or announce an award - Unique Requirements: - No procurement requirements or technical specifications are provided
Description
The Securities and Exchange Commission published a notice regarding Daxor Corporation's application for deregistration under section 8(f) of the Investment Company Act of 1940. The application was filed on February 9, 2026, and amended multiple times, with the latest amendment on September 4, 2026. Daxor Corporation, originally incorporated in 1971, operates as a radiopharmaceutical company and medical device manufacturer, and has ceased to be an investment company as it no longer holds investment securities. The Commission will issue an order granting the request unless a hearing is ordered, with hearing requests due by September 29, 2026.